Growth Hormone Releasing Hormone (GHRH) Analogue
Disclaimer: This product is for laboratory research purposes only. Not for human consumption.
Standardized handling, dosing, and storage guidelines for Tesamorelin in lipolytic and metabolic research applications.
Tesamorelin is a synthetic peptide consisting of 44 amino acids and acts as a highly potent analogue of growth hormone-releasing hormone (GHRH). It is primarily researched for its unique ability to significantly reduce visceral adipose tissue (VAT) and improve metabolic profiles without disrupting natural glucose homeostasis or causing severe insulin resistance. By stimulating the pituitary gland to release endogenous growth hormone in a pulsatile manner, it facilitates targeted lipolysis and systemic metabolic improvements.
Rapid binding to GHRH receptors, initiating physiological pulses of Growth Hormone. Subjects often exhibit early improvements in sleep architecture and mild thermogenic responses.
| Compound | Primary Mechanism | Key Benefit | Admin. |
|---|---|---|---|
| Tesamorelin | GHRH Analogue (44 AA) | Targeted visceral fat reduction | SubQ |
| CJC-1295 w/ DAC | Long-acting GHRH | Sustained GH pulses & IGF-1 elevation | SubQ |
| Ipamorelin | GHRP (Secretagogue) | Synergistic GH release without cortisol spikes | SubQ |
| Tirzepatide | GLP-1/GIP Agonist | Systemic weight loss & glycemic control | SubQ |
Tesamorelin features a trans-3-hexenoic acid group attached to the N-terminus, which protects it from rapid degradation and enhances its binding affinity to pituitary receptors.
Binds strongly to growth hormone-releasing hormone receptors on somatotrophs in the anterior pituitary gland.
Stimulates the natural, pulsatile release of endogenous growth hormone into the systemic circulation.
The elevated GH levels upregulate lipolytic enzymes specifically in visceral adipose tissue, mobilizing stored triglycerides for energy.
Relatively short half-life (approx. 8-12 minutes), but induces a prolonged GH secretory response.
High via subcutaneous injection; requires daily administration for optimal lipid metabolism effects.
Rapidly degraded by dipeptidyl peptidase IV (DPP-IV) and cleared renally.
Highly specific for GHRH receptors on somatotropes in the anterior pituitary.
Tesamorelin is widely recognized as one of the most effective peptides for targeted reduction of visceral fat without compromising insulin sensitivity.
Explores how GHRH analogues upregulate lipolytic enzymes specifically in VAT deposits.
GLUCOSE HOMEOSTASISA deep dive into why stimulating endogenous GH preserves insulin sensitivity.
METABOLIC SYNDROMEReviews the efficacy of Tesamorelin in reducing triglycerides and elevating HDL.
Explore research-use products associated with this compound profile, including available formats, related blends, and supporting lab documentation where available.
Common research-focused questions about Tesamorelin, lab documentation, storage considerations, and how this compound is positioned within research-use workflows.
Tesamorelin is a synthetic growth hormone-releasing hormone analogue studied in endocrine, metabolic, and growth hormone axis research contexts. On this site, Tesamorelin is positioned strictly as a laboratory research reference compound.
Yes. Tesamorelin products listed on Symbiotic Pharmaceuticals are intended for laboratory research and analytical reference use only. They are not intended for human consumption, animal consumption, diagnostic use, therapeutic use, or self-administration.
Storage requirements can vary by product format, batch, and label instructions. For research handling, follow the product label and applicable laboratory storage standards, while avoiding unnecessary exposure to heat, light, moisture, or repeated temperature changes.
Available certificates of analysis and batch documentation can be reviewed through the Lab Results / COA page. Documentation availability may vary by product and inventory lot.
Tesamorelin is commonly referenced in research involving growth hormone-releasing hormone pathways, endocrine signaling, metabolic models, body composition research, and IGF-1 related laboratory endpoints.
Tesamorelin, Sermorelin, and CJC-1295 are all discussed in relation to growth hormone-releasing hormone research, but they differ in structure, modification profile, and research context. Tesamorelin is typically categorized as a modified GHRH analogue in research reference materials.
Tesamorelin orders are prepared with discreet packaging and handled according to product type. Shipping timelines and handling options may vary by location, order contents, and carrier availability.
